BostonGene to Showcase AI Foundation Models for Precision Immuno-Oncology at RadMed Symposium
Event summary
- BostonGene will present at the 22nd Annual RadMed Symposium on June 11, 2026, in San Diego.
- The presentation will focus on AI foundation models integrating multimodal oncology and immunology data.
- Dr. Michael F. Goldberg, VP of R&D at BostonGene, will highlight clinical study findings on predicting immunotherapy response and toxicity.
- The event will explore advancements in AI, immuno-oncology, molecular imaging, and targeted therapies.
The big picture
BostonGene's presentation at the RadMed Symposium underscores the growing intersection of AI and precision oncology, where advanced AI models are being leveraged to decode complex tumor-immune interactions. This aligns with broader industry trends towards data-driven, personalized medicine, particularly in immuno-oncology, where AI is expected to accelerate drug discovery and improve patient outcomes. The strategic focus on integrating multimodal data highlights the potential for AI to create a scalable decision layer in oncology, enhancing both clinical management and therapeutic strategy.
What we're watching
- AI Integration
- How BostonGene's AI foundation models will impact the pace of drug development and clinical decision-making.
- Clinical Validation
- Whether the clinical study findings can be replicated and scaled across different indications.
- Market Adoption
- The pace at which biopharmaceutical partners will adopt BostonGene's AI-driven precision oncology solutions.
Related topics